{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:32:30Z","timestamp":1790937150137,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.drudis.2022.05.020","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T12:18:02Z","timestamp":1653653882000},"page":"2586-2592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Prospects of halofuginone as an antiprotozoal drug scaffold"],"prefix":"10.1016","volume":"27","author":[{"given":"Jasmita","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.05.020_b0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3389\/fphar.2020.00397","article-title":"Unraveling plant natural chemical diversity for drug discovery purposes","volume":"11","author":"Lauti\u00e9","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2022.05.020_b0010","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/161400b0","article-title":"Pharmacology of Ch\u2019ang Shan (Dichroa febrifuga), a Chinese antimalarial herb","volume":"161","author":"Jang","year":"1948","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.05.020_b0015","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1128\/AAC.49.3.1169-1176.2005","article-title":"Antimalarial activities and therapeutic properties of febrifugine analogs","volume":"49","author":"Jiang","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.05.020_b0020","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.bmc.2014.02.040","article-title":"The chemistry and biology of febrifugine and halofuginone","volume":"22","author":"McLaughlin","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2022.05.020_b0025","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1021\/jm0601809","article-title":"Exploration of a new type of antimalarial compounds based on febrifugine","volume":"49","author":"Kikuchi","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.05.020_b0030","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.bmc.2011.11.053","article-title":"Febrifugine analogue compounds: synthesis and antimalarial evaluation","volume":"20","author":"Zhu","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2022.05.020_b0035","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1016\/j.ejmech.2010.05.040","article-title":"Synthesis and evaluation of 4-quinazolinone compounds as potential antimalarial agents","volume":"45","author":"Zhu","year":"2010","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2022.05.020_b0040","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.bmc.2018.04.027","article-title":"Chemical synthesis of febrifugine and analogues","volume":"26","author":"Smullen","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2022.05.020_b0045","unstructured":"European Medicines Agency. Halocur (halofuginone). https:\/\/www.ema.europa.eu\/en\/medicines\/veterinary\/EPAR\/halocur. Accessed September 5, 2021."},{"key":"10.1016\/j.drudis.2022.05.020_b0050","unstructured":"NOAH Compendium. Stenorol\u00ae (halofuginone Hydrobromide). https:\/\/www.noahcompendium.co.uk\/?id=-453094. Accessed December 22, 2021."},{"key":"10.1016\/j.drudis.2022.05.020_b0055","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/1098-2299(200007\/08)50:3\/4<371::AID-DDR19>3.0.CO;2-R","article-title":"Halofuginone: from veterinary use to human therapy","volume":"50","author":"Pines","year":"2000","journal-title":"Drug Develop Res"},{"key":"10.1016\/j.drudis.2022.05.020_b0060","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/QAI.0b013e3181fc0141","article-title":"Phase II AIDS malignancy consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma","volume":"56","author":"Koon","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.drudis.2022.05.020_b0065","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1083-8791(03)00151-4","article-title":"Halofuginone to treat fibrosis in chronic graft versus host disease and scleroderma","volume":"9","author":"Pines","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.drudis.2022.05.020_b0070","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.ejca.2005.12.027","article-title":"EORTC New Drug Development Group (NDDG). Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours","volume":"42","author":"de Jonge","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.drudis.2022.05.020_b0075","article-title":"The prolyl-tRNA synthetase inhibitor halofuginone inhibits SARS-CoV-2 infection","author":"Sandoval","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.drudis.2022.05.020_b0080","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1038\/s41467-021-24156-y","article-title":"A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry","volume":"12","author":"Chen","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2022.05.020_b0085","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/bs.enz.2020.07.001","article-title":"Aminoacyl-tRNA synthetases as drug targets","volume":"48","author":"Lukarska","year":"2020","journal-title":"Enzymes"},{"key":"10.1016\/j.drudis.2022.05.020_b0090","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/emmm.201100626","article-title":"Aminoacyl-tRNA synthetases in medicine and disease","volume":"5","author":"Yao","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.drudis.2022.05.020_b0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nchembio.790","article-title":"Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase","volume":"8","author":"Keller","year":"2012","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2022.05.020_b0100","doi-asserted-by":"crossref","unstructured":"Herman JD, Pepper LR, Cortese JF, Estiu G, Galinsky K, Zuzarte-Luis V, et al. The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs. Sci Transl Med 2015;7:288ra77.","DOI":"10.1126\/scitranslmed.aaa3575"},{"key":"10.1016\/j.drudis.2022.05.020_b0105","unstructured":"World Health Organization. Malaria. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/malaria. Accessed September 5, 2021."},{"key":"10.1016\/j.drudis.2022.05.020_b0110","doi-asserted-by":"crossref","unstructured":"The malERA Refresh Consultative Panel on Insecticide and Drug Resistance. malERA: an updated research agenda for insecticide and drug resistance in malaria elimination and eradication. PLoS Med 2017;14:e1002450.","DOI":"10.1371\/journal.pmed.1002450"},{"key":"10.1016\/j.drudis.2022.05.020_b0115","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.2147\/DDDT.S265602","article-title":"Recent progress in the development of new antimalarial drugs with novel targets","volume":"14","author":"Mulaw","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.drudis.2022.05.020_b0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10969-014-9186-x","article-title":"Structural and functional analysis of the antimalarial drug target prolyl-tRNA synthetase","volume":"15","author":"Jain","year":"2014","journal-title":"J Struct Funct Genomics"},{"key":"10.1016\/j.drudis.2022.05.020_b0125","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.str.2015.02.011","article-title":"Structure of prolyl-tRNA synthetase-halofuginone complex provides basis for development of drugs against malaria and toxoplasmosis","volume":"23","author":"Jain","year":"2015","journal-title":"Structure"},{"key":"10.1016\/j.drudis.2022.05.020_b0130","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.str.2017.07.015","article-title":"Targeting prolyl-tRNA synthetase to accelerate drug discovery against malaria, leishmaniasis, toxoplasmosis, cryptosporidiosis, and coccidiosis","volume":"25","author":"Jain","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.drudis.2022.05.020_b0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature11774","article-title":"ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase","volume":"494","author":"Zhou","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.05.020_b0140","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1107\/S0907444913020556","article-title":"Conformational changes in human prolyl-tRNA synthetase upon binding of the substrates proline and ATP and the inhibitor halofuginone","volume":"69","author":"Son","year":"2013","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.drudis.2022.05.020_b0145","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1186\/s13059-014-0511-2","article-title":"A genomic and evolutionary approach reveals non-genetic drug resistance in malaria","volume":"15","author":"Herman","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.drudis.2022.05.020_b0150","doi-asserted-by":"crossref","unstructured":"O\u2019Leary JK, Sleator RD, Lucey B.Cryptosporidiumspp. diagnosis and research in the 21stcentury.Food Waterborne Parasitol 2021;24:e00131.","DOI":"10.1016\/j.fawpar.2021.e00131"},{"key":"10.1016\/j.drudis.2022.05.020_b0155","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1017\/S0031182020002267","article-title":"Efficacy of halofuginone products to prevent or treat cryptosporidiosis in bovine calves: a systematic review and meta-analyses","volume":"148","author":"Brainard","year":"2021","journal-title":"Parasitology"},{"key":"10.1016\/j.drudis.2022.05.020_b0160","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tvjl.2007.05.007","article-title":"Preventive and therapeutic efficacy of halofuginone-lactate against Cryptosporidium parvum in spontaneously infected calves: a centralised, randomized, double-blind, placebo-controlled study","volume":"177","author":"Klein","year":"2008","journal-title":"Vet J"},{"key":"10.1016\/j.drudis.2022.05.020_b0165","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1073\/pnas.1814685116","article-title":"Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis","volume":"116","author":"Baraga\u00f1a","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2022.05.020_b0170","doi-asserted-by":"crossref","unstructured":"Vinayak S, Jumani RS, Miller P, Hasan MM, McLeod BI, Tandel J, et al. Bicyclic azetidines kill the diarrheal pathogenCryptosporidiumin mice by inhibiting parasite phenylalanyl-tRNA synthetase. Sci Transl Med 2020;12:eaba8412.","DOI":"10.1126\/scitranslmed.aba8412"},{"key":"10.1016\/j.drudis.2022.05.020_b0175","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1007\/s00436-018-6000-x","article-title":"Molecular characterisation and risk factor analysis of Cryptosporidium spp. in calves from Italy","volume":"117","author":"D\u00edaz","year":"2018","journal-title":"Parasitol Res"},{"key":"10.1016\/j.drudis.2022.05.020_b0180","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.vetpar.2018.01.018","article-title":"Treatment of cryptosporidiosis in captive green iguanas (Iguana iguana)","volume":"252","author":"Ga\u0142\u0119cki","year":"2018","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.drudis.2022.05.020_b0185","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1016\/j.bmcl.2007.05.053","article-title":"(2R,3S)-(+)- and (2S,3R)-(\u2212)-halofuginone lactate: synthesis, absolute configuration, and activity against Cryptosporidium parvum","volume":"17","author":"Linder","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"issue":"197","key":"10.1016\/j.drudis.2022.05.020_b0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vetpar.2013.04.029","article-title":"Utility of halofuginone lactate for the prevention of natural cryptosporidiosis of calves, in the presence of co-infection with rotavirus and Salmonella Typhimurium","volume":"18","author":"Almawly","year":"2013","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.drudis.2022.05.020_b0195","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.vetpar.2013.03.003","article-title":"Integration of halofuginone lactate treatment and disinfection with p-chloro-m-cresol to control natural cryptosporidiosis in calves","volume":"196","author":"Keidel","year":"2013","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.drudis.2022.05.020_b0200","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3382\/ps.2013-03634","article-title":"Milestones in avian coccidiosis research: a review","volume":"93","author":"Chapman","year":"2014","journal-title":"Poult Sci"},{"key":"10.1016\/j.drudis.2022.05.020_b0205","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3382\/ps.0581483","article-title":"Efficacy of stenorol (halofuginone). III. For the control of coccidiosis in turkeys","volume":"58","author":"Edgar","year":"1979","journal-title":"Poult Sci"},{"key":"10.1016\/j.drudis.2022.05.020_b0210","doi-asserted-by":"crossref","unstructured":"EFSA Panelon Additives and Products or Substances used in Animal Feed (FEEDAP), Bampidis V, Azimonti G, Bastos ML, Christensen H, Dusemund B, et al. Safety and efficacy of STENOROL\u00ae(halofuginone hydrobromide) as a feed additive for chickens for fattening and turkeys. EFSA J 2020;18:e06169.","DOI":"10.2903\/j.efsa.2020.6169"},{"key":"10.1016\/j.drudis.2022.05.020_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0304-4017(88)90013-1","article-title":"Anticoccidial evaluation of halofuginone, lasalocid, maduramicin, monensin and salinomycin","volume":"28","author":"Folz","year":"1988","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.drudis.2022.05.020_b0220","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3390\/molecules22071086","article-title":"A novel synthesis of the efficient anti-coccidial drug halofuginone hydrobromide","volume":"22","author":"Zhang","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2022.05.020_b0225","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.taap.2010.12.014","article-title":"Risk assessment of coccidostatics during feed cross-contamination: animal and human health aspects","volume":"270","author":"Dorne","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.drudis.2022.05.020_b0230","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3382\/ps\/pew499","article-title":"Prevalence and drug resistance of avian Eimeria species in broiler chicken farms of Zhejiang province","volume":"96","author":"Lan","year":"2017","journal-title":"China. Poult Sci"},{"key":"10.1016\/j.drudis.2022.05.020_b0235","unstructured":"World Health Organization. Toxoplasmosis factsheet. https:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0011\/294599\/Factsheet-Toxoplasmosis-en.pdf. Published 2015. Accessed September 5, 2021."},{"key":"10.1016\/j.drudis.2022.05.020_b0240","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fmicb.2017.00025","article-title":"A systematic review of in vitro and in vivo activities of anti-toxoplasma drugs and compounds (2006\u20132016)","volume":"8","author":"Montazeri","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.drudis.2022.05.020_b0245","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1128\/AAC.02009-15","article-title":"Clinically available medicines demonstrating anti-toxoplasma activity","volume":"59","author":"Neville","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.05.020_b0250","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1107\/S2053230X19014808","article-title":"Conformational heterogeneity in apo and drug-bound structures of Toxoplasma gondii prolyl-tRNA synthetase","volume":"75","author":"Mishra","year":"2019","journal-title":"Acta Crystallogr F Struct Biol Commun"},{"key":"10.1016\/j.drudis.2022.05.020_b0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010363","article-title":"Double drugging of prolyl-tRNA synthetase provides a new paradigm for anti-infective drug development","volume":"18","author":"Manickam","year":"2022","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2022.05.020_b0260","unstructured":"World Health Organization. Leishmaniasis. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis. Accessed September 5, 2021."},{"key":"10.1016\/j.drudis.2022.05.020_b0265","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/ced.14919","article-title":"Comprehensive review on treatment options of leishmaniasis","volume":"47","author":"Pradhan","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.drudis.2022.05.020_b0270","unstructured":"Chang HM, But PP, editors. Pharmacology and applications of Chinese material medicine. Singapore: World Scientific Publishing; 1986\u20131987."},{"key":"10.1016\/j.drudis.2022.05.020_b0275","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/acsinfecdis.6b00078","article-title":"Biochemical and structural characterization of selective allosteric inhibitors of the Plasmodium falciparum drug target, prolyl-tRNA-synthetase","volume":"3","author":"Hewitt","year":"2017","journal-title":"ACS Infect Dis"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622002100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622002100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:57:54Z","timestamp":1761224274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644622002100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1359644622002100"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.05.020","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospects of halofuginone as an antiprotozoal drug scaffold","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}